Capricor Therapeutics is exploding higher today despite a heavy wave of negative news regarding a securities class action lawsuit filed against the company. Multiple law firms have issued alerts to investors following revelations that the FDA criticized the company for undisclosed changes to the statistical analysis plan for its lead drug candidate, Deramiocel. This regulatory scrutiny, which previously triggered a 64% decline in the stock price, remains a focal point as investors are urged to contact counsel before the September 28, 2026, lead plaintiff deadline.